Carisbamate
- Generic Name
- Carisbamate
- Drug Type
- Small Molecule
- Chemical Formula
- C9H10ClNO3
- CAS Number
- 194085-75-1
- Unique Ingredient Identifier
- P7725I9V3Z
- Background
Carisbamate has been investigated in Alcohol Abuse, Substance Abuse, and Alcohol Dependence.
Investigate Efficacy and Safety of Carisbamate As Adjunctive Treatment for Seizures Associated with LGS in Children and Adults
- First Posted Date
- 2022-02-02
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- SK Life Science, Inc.
- Target Recruit Count
- 252
- Registration Number
- NCT05219617
- Locations
- 🇺🇸
Stanford University Hospital, Palo Alto, California, United States
🇺🇸University of Florida Health Science Center, Jacksonville, Florida, United States
🇺🇸AdventHealth, Orlando, Florida, United States
Bioavailability and Food Effect Study of 3 Types of Carisbamate
- First Posted Date
- 2020-08-20
- Last Posted Date
- 2021-10-07
- Lead Sponsor
- SK Life Science, Inc.
- Target Recruit Count
- 33
- Registration Number
- NCT04520360
- Locations
- 🇺🇸
PRA Health Sciences- Salt Lake City, Salt Lake City, Utah, United States
Carisbamate Safety Study in Adult and Pediatric Subjects With Lennox-Gastaut Syndrome
- First Posted Date
- 2019-08-20
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- SK Life Science, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT04062981
- Locations
- 🇺🇸
UW Valley Medical Center, Renton, Washington, United States
🇺🇸Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
Carisbamate in Adult & Pediatric Subjects With Lennox-Gastaut Syndrome
- First Posted Date
- 2018-11-06
- Last Posted Date
- 2023-05-30
- Lead Sponsor
- SK Life Science, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT03731715
- Locations
- 🇺🇸
Duke Health, Durham, North Carolina, United States
🇺🇸Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸UW Valley Medical Center, Renton, Washington, United States
Carisbamate as a Potential Treatment for Alcohol Dependence
- Conditions
- Alcohol DependenceAlcohol AbuseSubstance Abuse
- Interventions
- Drug: Placebo
- First Posted Date
- 2015-05-06
- Last Posted Date
- 2021-03-02
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 11
- Registration Number
- NCT02435381
- Locations
- 🇺🇸
Michael E. DeBakey VA Medical Center, Houston, Texas, United States
An Open-Label Extension Study to Evaluate the Safety and Tolerability of RWJ 333369 as Adjunctive Therapy in Patients 16 Years and Older With Partial Onset Seizures.
- Conditions
- Complex Partial SeizuresEpilepsy, Complex PartialEpilepsies, PartialEpilepsy
- Interventions
- First Posted Date
- 2009-10-08
- Last Posted Date
- 2013-06-18
- Lead Sponsor
- SK Life Science, Inc.
- Target Recruit Count
- 991
- Registration Number
- NCT00991757
An Efficacy and Safety Study of Carisbamate in the Treatment of Nerve Pain in Diabetics
- Conditions
- Diabetic Neuropathies
- Interventions
- First Posted Date
- 2009-03-27
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- SK Life Science, Inc.
- Target Recruit Count
- 386
- Registration Number
- NCT00870454
An Open-Label Extension Study of the Safety and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset Seizures
- Conditions
- Epilepsy, Partial, MotorEpilepsy, Complex PartialEpilepsy, Simple PartialFocal Motor Epilepsy
- Interventions
- Drug: placebo
- First Posted Date
- 2008-09-01
- Last Posted Date
- 2013-06-18
- Lead Sponsor
- SK Life Science, Inc.
- Target Recruit Count
- 403
- Registration Number
- NCT00744731
A Study of the Effectiveness, Safety, and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset Seizures.
- Conditions
- Epilepsy, Partial, MotorEpilepsy, Complex PartialEpilepsy, Simple PartialFocal Motor Epilepsy
- Interventions
- Drug: placebo
- First Posted Date
- 2008-08-25
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- SK Life Science, Inc.
- Target Recruit Count
- 547
- Registration Number
- NCT00740623
Effectiveness and Safety Study for RWJ-333369 as Adjunctive Therapy in Korean and Japanese Patients With Partial Onset Seizures
- First Posted Date
- 2008-06-16
- Last Posted Date
- 2013-01-23
- Lead Sponsor
- SK Life Science, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT00697762
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.